268600.KQ Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 kov. 2023 @ 08:30):

Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening lethal diseases, such as cancer, inflammation, metabolic, and neurodegenerative diseases...

Stats
Dzisiejszy wolumen	0.00
Średni wolumen	1.15M
Kapitalizacja rynkowa	244.94B
EPS	KRW0 ( 2024-03-21 )
Następna data zysków	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW904.38 (13.54%)

Wolumen Korelacja

Długi: 0.03 (neutral)

Krótki: -0.87 (strong negative)

Signal:(24.963) Be Aware. Possible trading coming up! (swing)

Cellivery Therapeutics, Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cellivery Therapeutics, Korelacja - Waluta/Towar

-0.06
( neutral )

0.14
( neutral )

-0.34
( neutral )

-0.26
( neutral )

0.27
( neutral )

0.32
( neutral )

Cellivery Therapeutics, Finanse

Annual	2023
Przychody:	KRW18.86B
Zysk brutto:	KRW-3.78B (-20.02 %)
EPS:	KRW-889.35

FY	2023
Przychody:	KRW18.86B
Zysk brutto:	KRW-3.78B (-20.02 %)
EPS:	KRW-889.35

FY	2022
Przychody:	KRW23.16B
Zysk brutto:	KRW-2.93B (-12.64 %)
EPS:	KRW-2 984.97

Financial Reports:

No articles found.

Cellivery Therapeutics,

Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening lethal diseases, such as cancer, inflammation, metabolic, and neurodegenerative diseases. It develops small molecule, antibody, and vaccine drugs based on its Therapeutic molecule Systemic Delivery Technology. The company was founded in 2014 and is based in Seoul, South Korea.